Mr Inderjit Singh's second point is that we should sharpen the focus of our biomedical strategy on niche areas, instead of just letting foreign researchers do what they want in Singapore. I agree. Let me explain our R&D strategy. First of all, we have decided to increase our National R&D expenditure to 3% of GDP. I thank Dr Loo Choon Yong for supporting such a strategy. By world standards, 3% of GDP is not very large, particularly when we consider the size of our GDP. Second, two-thirds of that expenditure would, in fact, be from the private sector. Hence, Government expenditure is only 1% of GDP. Third, Government expenditure has to be apportioned to the BMS sector as well as the non-BMS sectors. In the non-BMS sectors, for example, we are very clear of our mission - to support and expand the existing sectors and grow new sectors, as I outlined just now. Fourth, with the limited funds available, therefore, we have to concentrate and we have to focus on niche areas. And this is indeed what we have been doing. We have recruited foreign scientists based on the strength that Singapore wants to compete on and develop, and also on how the foreign scientists can help train and nurture our local talent. Furthermore, A*STAR does not work alone. In cancer research, for example, it collaborates with other leading research institutions, such as Sweden's Karolinska Institute. Our capabilities are well recognised internationally, due to the critical mass of excellent research talent that we have managed to attract internationally. At the same time, we are developing a healthy pipeline of our local researchers. A*STAR has so far awarded close to 400 scholarships in the field of BMS.